Despite several economic reforms in India post-1991, millions of Indian households do not have access to drugs because they lack purchasing power or public health facilities. The present article critically examines the potential public health implication of trade liberalization to facilitate access to a variety of good quality drugs at affordable costs. Using the partial equilibrium model, the article suggests that multilateralism and free trade agreements (FTAs) both have a positive impact on welfare gains, consumer surplus, and trade volume in pharmaceutical industries in India. However, the study found that multilateralism is clearly associated with improved human welfare, particularly health. Multilateral trade liberalization should, therefore, be viewed in terms of its wider socioeconomic impact, rather than through the narrow lens of country-specific FTAs.
KotwaniAEwenMDeyD, et al.
Prices and availability of common medicines at six sites in India using a standard methodology.Indian J Med Res. 2007;
125:645–54.
6.
KotwaniAChaudhuryRHollowayK.Antibiotic prescribing practices of primary care prescribers for acute diarrhea in New Delhi, India.Value Health. 2012;
6:S116–S119.
7.
CarlosMC.Implications of the Doha Declaration on the TRIPS Agreement and Public Health (Weissman R, ed). Geneva, Switzerland: World Health Organization. Health Economics and Drugs; EDM Series no.12. https://apps.who.int/medicinedocs/pdf/s2301e/s2301e.pdf. Published 2002. Accessed December 10, 2019.
8.
Health Savings Accounts in India. KPMG (Klynveld Peat Marwick Goerdele) and FICCI (Federation of Indian Chambers of Commerce & Industry) jointly published a report. http://ficci.in/spdocument/22928/FICCI_KPMG_HSA_KP.pdf. Published December 2017. Accessed December 10, 2019.
9.
ArchanaV.The potential impact of China – India Free Trade Agreement on Chinese and Indian industries.China Econ J. 2019;
12:297–315.
10.
SmithRDCorreaCOhC.Trade, TRIPS, and pharmaceuticals.Lancet. 2009;
373(9664):684–691.
11.
LindstromB.Scaling back TRIPS-Plus: an analysis of intellectual property provisions in trade agreements and implications for Asia and the Pacific.Int Law Polit. 2010;
42:917–980.
12.
GleesonDFrielS.Emerging threats to public health from regional trade agreements.Lancet. 2013;
381(9876):1507–1509.
FlynnSBakerBKaminskiMKooJ.The US proposal for an IP chapter in the Trans-Pacific Partnership.Am Univ Int Law Rev. 2012:
1(28):106–202.
15.
TrachtmanJP. Development Aspects of a Trans-Pacific Partnership. doi:10.2139/ssrn.1953943. http://papers.ssrn.com. Published 2011. Accessed December 10, 2019.
16.
KessomboonKLimpananontJKulsomboonV.Impact on access to medicines from TRIPs-plus: a case study of Thai-US FTA. Southeast Asian J Trop Med Public Health.2010;
3(41):667–677.
17.
AkaleephanCWibulpolprasertSSakulbumrungsilR, et al.
Extension of market exclusivity and its impact on the accessibility to essential medicines and drug expense in Thailand: analysis of the effect of the TRIPs-plus proposal.Health Policy. 2009;
91(2):174–182.
18.
ChaudhuriS.Is Product Patent Protection Necessary in Developing Countries for Innovation? R&D by Indian Pharmaceutical Companies After TRIPs. Working Papers Series No. 614.
Calcutta, India:
Indian Institute of Management; 2007.
19.
ChadhaA.TRIPs and patenting activity: evidence from the Indian Pharmaceutical Industry.Econ Modell. 2009;
26(2):499–505.
20.
BediNBediPMSSoochBS.Patenting and R&D in Indian pharmaceutical industry: post TRIPS scenario. J Intellect Prop Rights. 2013;
18(2):105–110.
21.
KiranRMishraS.Changing pragmatics of the Indian pharmaceutical industry in the pre and post TRIPS period.Int J Bus Manag. 2009;
4:206–220.
22.
FinkC.How Stronger Patent Protection in India Might Affect the Behavior or Transnational Pharmaceutical Industries. World Bank Policy Research Working Paper No. 2352. http://wwwwds.worldbank.org. Published 2000. Accessed December 10, 2019.
23.
WatalJ.Pharmaceutical patents, prices and welfare losses: policy options for India under the WTO TRIPS agreement.World Econ. 2000;
23(5):733–752.
24.
ChaudhuriS.GoldbergPKJiaP.Estimating the effects of global patent protection in pharmaceuticals: a case study of quinolones in India.Am Econ Rev. 2006;
96(5):1477–1514.
25.
HafnerTPoppD.China and India as Suppliers of Affordable Medicines to Developing Countries. Working Paper 17249. http://www.nber.org/papers/w17249. Published 2011. Accessed December 10, 2019.
26.
SreekanthVPhilipS.Are Free Trade Agreements Bad for Health? Quantifying the Impact of FTAs on Health Outcomes. Working Paper. https://geneva-network.com. Published 2015. Accessed December 10, 2019.
27.
OwenAWuS.Is trade good for your health?Rev Int Econ. 2007;
15(4);660–682.
28.
StevensPUrbachJWillsG.Healthy trade: the relationship between open trade and health.Foreign Trade Rev. 2013;
48(1):125–135.
29.
HerzerD. The long-run relationship between trade and population health: evidence from five decades. Conference Session: Development II. No. B01-V1; 2014.
30.
SrinivasanTN.Global trading system: decline of non-discrimination and rise of preferential trade arrangements and agreements.Stanford J Int Law. 2010;
46(2):199–217.
31.
SrinivasanTNVaniA.India in the Global and Regional Trade: Determinants of Aggregate and Bilateral Flows and Firm’s Decision to Export. Stanford Centre for International Development. Working Paper No. 393; 2009.
32.
KehoePJKehoeTJ.A primer on static applied general equilibrium models. Fed Reserve BankMinneap Q Rev. 1994;
18:2–16.
33.
NguyenBD.Forecasting Impacts of the European – Vietnam Free Trade Agreement on Vietnam’s Economy.
Hanoi, Vietnam:
Foreign Trade University; 2014.
34.
CallaghanAB.How is the EU-ASEAN FTA viewed by ASEAN stakeholders.Asia Eur J. 2009;
7:63–78.
35.
CassingJTrewinRVanzettiD, et al. Impact Assessment of Free Trade Agreement on Vietnam’s Economy.
Hanoi, Vietnam:
MUTRAP III; 2010.
36.
AhmedS.India-ASEAN Free Trade Agreement: A Sectoral Analysis. SSRN Working Paper 1698849. doi:10.2139/ssrn.1698849. http://ssrn.com/abstract=1698849. Published 2010. Accessed February 12, 2016.
37.
CheongD.Methods for ex-ante economic valuation of free trade agreements, in ADB. Work Pap Ser Region Econ Integr. 2010;
52:1–48.
38.
OthienoLShinyekwaI.Trade, Revenue and Welfare Effects of the East African Community Customs Union Principle of Asymmetry on Uganda: An Application of Wits-Smart Simulation Model.
Kampala, Uganda:
Economic Policy Research Centre; 2011.
39.
ChoudhrySKallummalMVarmaP.Trade Creation and Trade Diversion in the India-Sri Lanka Free Trade Agreement-A Sector Specific Analysis. Working Paper CS/WP/200/11, Center for WTO Studies.
New Delhi, India:
Indian Institute of Foreign Trade; 2013.
MahalABibekDLaveeshB.India Health Report.
New Delhi, India:
Business Standard; 2010.
43.
SkathivelSNambarV.Access to medicine in India: issues, challenges and policy options. In: MahalABibekDLaveeshB, eds. India Health Report. 1st ed.
New Delhi, India:
Business Standard; 2010:83–96.
44.
BigdeliMJacobsBTomsonG, et al.
Access to medicines from a health system perspective.Health Policy Plan. 2013;
28(7):692–704.
